Orgovyx Shortage: What Providers and Prescribers Need to Know in 2026

Orgovyx (relugolix) represents a significant advance in androgen deprivation therapy (ADT) for advanced prostate cancer — the first oral GnRH antagonist approved by the FDA, offering rapid testosterone suppression without the flare associated with GnRH agonists, and demonstrating a 54% lower rate of major adverse cardiovascular events compared to leuprolide in the Phase 3 HERO trial. However, your patients are encountering real-world access barriers that require clinical teams to proactively manage the prescription and fulfillment process.

Current Access Status: Not a Supply Shortage, but a Distribution Gap

As of 2026, Orgovyx is not listed on the FDA Drug Shortage Database. The manufacturer (Sumitomo Pharma America) is producing the drug, and it is available through specialty pharmacy networks. The access gaps that patients and practices experience arise from:

Prior authorization (PA) requirements on virtually all commercial and Medicare Part D plans

Specialty-only distribution — exclusive to specialty pharmacy networks, unavailable at retail pharmacies

High specialty tier placement — creating cost-sharing barriers even after PA approval

Step therapy requirements on some plans, requiring documented failure or intolerance of injectable GnRH agonists

Prior Authorization: Strategies for Expediting Approval

PA approval is the most consistent bottleneck. Based on the clinical evidence available, here are approaches to strengthen PA requests and appeal outcomes:

Document cardiovascular risk factors explicitly. The HERO trial data showing a 54% lower MACE rate with relugolix versus leuprolide is compelling for patients with prior cardiac events, hypertension, or atrial fibrillation. Include this in your medical necessity letter.

Note the oral route preference. For patients with needle phobia, mobility limitations, or who cannot make regular clinic visits for injections, document this clearly.

Cite NCCN Guidelines. Orgovyx is included in the NCCN Clinical Practice Guidelines in Oncology (Prostate Cancer) as an ADT option with a Category 2A recommendation.

Use the Orgovyx Support Program. Call 1-833-ORGOVYX (1-833-674-6899). The manufacturer's hub program has reimbursement specialists who assist with PA submissions, benefit investigations, and appeals at no cost to your practice.

Request peer-to-peer review for denied PAs. A phone call between your clinical team and the insurance plan's medical director can often overturn denials when the cardiovascular benefit data is presented.

Specialty Pharmacy Logistics: What Your Office Needs to Know

Orgovyx prescriptions must be routed to a specialty pharmacy, not a retail pharmacy. Establish a workflow in your office to:

Verify the patient's in-network specialty pharmacy before sending the prescription

Send the prescription electronically to the correct specialty pharmacy location (not the retail division)

Follow up on PA status within 3-5 business days of submission

Counsel patients that a specialty pharmacy will contact them by phone — advise them to answer unfamiliar numbers

Build refill reminders into your follow-up schedule — patients should never be down to their last 7-day supply

Manufacturer Support for Practices

The Orgovyx hub program offers the following at no cost to practices:

Benefits verification and PA submission support

Appeals support with letters of medical necessity templates

Patient copay assistance enrollment ($10/month copay cap for eligible commercially insured patients)

Bridge Program access (up to 4 months of free drug during coverage gaps)

Clinical Alternatives When Orgovyx Access Fails

If a patient's access to Orgovyx is delayed and treatment cannot wait:

Degarelix (Firmagon): Most mechanistically similar (GnRH antagonist, no flare), can be administered in-office monthly. Appropriate bridge for patients with cardiovascular risk or symptomatic metastatic disease.

Leuprolide (Lupron Depot, Eligard): GnRH agonist; risk of initial testosterone flare. Lower cost with generic availability. Consider antiandrogen co-treatment for the first 2-4 weeks in patients with metastatic disease to blunt flare effects.

Orchiectomy: Permanent surgical castration may be appropriate in select cases and achieves immediate, sustained testosterone suppression.

Connecting Patients to medfinder for Pharmacy Location Help

medfinder is a service that calls pharmacies on behalf of patients to identify which specialty pharmacies have Orgovyx in stock and can fill it. Referring your patients to medfinder.com/providers is a practical way to reduce the burden on your practice while ensuring patients can locate their medication efficiently.